Bristol Myers reports Phase 2 success for GPRC5D‑directed CAR‑T therapy

Bristol Myers announced positive Phase 2 results for its GPRC5D‑directed CAR‑T therapy aimed at treating multiple myeloma. The study demonstrated encouraging efficacy signals, adding to the growing impact of CAR‑T approaches in blood cancers.

The report highlights that while CAR‑T has transformed treatment, a key concern remains about options for patients whose disease progresses after receiving such therapy. Bristol Myers suggests its GPRC5D‑targeted product could address this unmet need.

No detailed efficacy numbers or safety data were provided in the brief article, but the company’s claim signals a potentially important advancement for relapsed or refractory myeloma patients.